Bioenvision's Evoltra(TM) (clofarabine) Prolongs Survival in Elderly AML Patients with Adverse Cytogenetics; Superior Response
June 05 2006 - 7:00AM
Business Wire
Bioenvision (Nasdaq: BIVN) today announced that in the companies
pivotal, non-randomized Phase II study (BIOV-121), presented at the
42nd Annual Meeting of the American Society of Clinical Oncology
(ASCO) in Atlanta, Evoltra(TM) (clofarabine) achieved a
substantially higher overall complete response rate and a longer
median survival than the current standard of care in elderly, high
risk patients with Acute Myeloid Leukemia (AML) who were considered
unsuitable for intensive treatment. All patients enrolled in the
study were greater than 65 years of age and had either intermediate
(70%) or adverse (30%) cytogenetics and the complete response (CR)
rates were 48% and 42% respectively. "These CR rates for Evoltra
are exceptional, for patients not considered fit for intensive
chemotherapy, when you consider that, in our previous studies, none
of the patients with adverse cytogenetics responded to our current
standard of care, low-dose ara-C (LDAC)," commented Professor Alan
Burnett, Chairman of the UK National Cancer Research Institute
(NCRI) Hematological Oncology Study Group. He added thatm, "it is
significant that the high response rates were seen in all age
groups from 65 to over 80 years." "In addition, the higher response
rates were translated into a clear survival benefit for patients
with the high risk cytogenetic profile. For patients with adverse
cytogenetics treated with Evoltra(TM) the median survival is
already over 6 months, with further follow up scheduled. In
comparison patients who are treated with the current standard of
care have a median survival of approximately one month," stated
Professor Burnett. "These exciting data will form the basis of our
filing of the Marketing Authorization Application in Europe for
this important new indication in elderly adult AML," said Hugh
Griffith, Bioenvision's Chief Operating Officer. He added, "This is
the next stage in the development strategy designed to position
Evoltra as the first-line agent of choice for all patients with
AML." About Evoltra(TM) (clofarabine) The European Marketing
Authorisation for Evoltra(TM) (clofarabine) is for "the treatment
of acute lymphoblastic leukemia (ALL) in pediatric patients who
have relapsed or are refractory to at least two prior regimens and
where there is no other treatment option anticipated to result in a
durable response. Safety and efficacy have been assessed in studies
of patients less than or equal to 21 years old at initial
diagnosis." Evoltra(TM) (clofarabine) is not currently approved for
adult AML. Clofarabine is in clinical development for the treatment
of numerous other hematological cancers and solid tumors.
Bioenvision is also conducting late-stage preclinical development
of Evoltra(TM) for the treatment of psoriasis and is planning
further worldwide development of Evoltra(TM) in autoimmune
diseases. Evoltra(TM) (clofarabine) is a next generation purine
nucleoside analog. Bioenvision holds an exclusive worldwide license
for clofarabine (outside Japan and Southeast Asia) and an
exclusive, irrevocable option to develop, market and distribute
clofarabine for all human applications in Japan and Southeast Asia.
Bioenvision granted an exclusive sublicense to Genzyme to
co-develop clofarabine for cancer indications in the US and Canada.
Genzyme is commercializing clofarabine for cancer indications in
the US and Canada under the brand name Clolar(R). Bioenvision holds
an exclusive license in the US and Canada for all non-cancer
indications. Bioenvision originally obtained clofarabine
development and commercialization rights under patents held by
Southern Research Institute. Clofarabine has been granted orphan
drug designation for the treatment of both ALL and AML in the U.S.
and Europe. In Europe, the designation provides marketing
exclusivity for 10 years following Marketing Authorization. About
Bioenvision Bioenvision's primary focus is the development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products
for the treatment of cancer, including: Evoltra(TM), Modrenal(R)
(for which Bioenvision has obtained regulatory approval for
marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products. Bioenvision is also developing
anti-infective technologies, including the OLIGON(R) technology, an
advanced biomaterial that has been incorporated into various FDA
approved medical devices and Suvus(R), an antimicrobial agent
currently in clinical development for refractory chronic hepatitis
C infection. For more information on Bioenvision please visit our
Web site at www.bioenvision.com. Certain statements contained
herein are "forward-looking" statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024